globenewswire news

NOTICE TO DISREGARD -- Leading Edge Health Inc

2026-08-12T22:00:35Z

LAS VEGAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- We are advised by VITALIBOOST LLC that journalists and other readers should disregard the news release, “Load Boost: Semenax, Volume Pills or SemEnhance - Which is Best Load Boost Supplements of 2025?” issued by Leading Edge Health Inc on May 1st, 2025, over GlobeNewswire.

Articles

Sanofi: Information concerning the total number of voting rights and shares - July 2026

2026-08-13T16:34:47Z

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of...

City of Mobile proclaims Project Persevere Day as The Helios Alliance Reports 117,444 Services Delivered in First Year of Opioid Abatement Program

2026-08-13T16:15:00Z

Sixteen organizations delivered 117,444 services at $143.81 per person — among the most efficient deployments of opioid settlement funds nationally — as a public awareness campaign prepares to launch

Aligned Marketplace Raises $20 Million, Achieves Measurable Outcomes with Large Employers

2026-08-13T16:00:00Z

A Third-Party Validated 12 Percent Reduction in Total Cost of Care Delivered in Year One For A Large Fortune 500 Company Proves the Independent Primary Care Model Works at Scale

Valneva Half-Year 2026 Financial Report

2026-08-13T15:45:00Z

Valneva Half-Year 2026 Financial Report

WellBridge Surgical Named No. 988 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America’s Fastest-Growing Private Companies

2026-08-13T15:11:46Z

Following Significant Revenue Growth Over the Past Three Years, Earning a Place Among the Nation’s Most Successful Independent Businesses

Tiny Health Named No. 208 on the 2026 Inc. 5000 List of America’s Fastest-Growing Private Companies

2026-08-13T15:03:13Z

Microbiome Innovator Recognized for 1,624% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses

Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026

2026-08-13T14:06:44Z

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026.

Early-Bird Deadline Approaches for 2nd Annual Guardian Initiative Charity Golf Tournament as Veterans Seek Sponsors to Play

2026-08-13T14:00:00Z

Players have until August 28 to take advantage of early-bird pricing for the September 28 charity tournament at Maderas Golf Club, while local veterans are seeking sponsors for the opportunity...

Arisan Therapeutics Selected for NIAID Contract Award to Develop a Therapeutic Small Molecule Viral Entry Inhibitor as a Medical Countermeasure for Filovirus Infection

2026-08-13T14:00:00Z

Contract Valued at Up to $24 million Supports IND-Enabling Studies for Arisan’s Lead Candidate with Demonstrated Activity Against Multiple Ebolaviruses

New MotherToBaby Study Targets Pregnancy Data Gap for Newer Eczema Treatment

2026-08-13T13:55:00Z

The FDA has determined that human pregnancy data for Ebglyss® remain insufficient. By enrolling U.S. and Canadian participants, this study will help generate the evidence needed to inform future treatment...

Acentra Health Awarded Five-Year Contract Extension to Continue Utilization Management Services in Colorado

2026-08-13T13:33:00Z

Contract allows state to promote quality and cost-effective healthcare for 1.3 million Coloradans

Meet Pomoni: Physician-Founded Polyphenol Brand Unveils New Name, New Olive Oil Supplement for Athletes

2026-08-13T13:15:00Z

Pomoni debuts Phenolia Endurance,Sponsors Iowa City's core4 Gravel Earth Series race

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

2026-08-13T13:15:00Z

Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside

MapLight Therapeutics Announces $150 Million Private Placement Financing

2026-08-13T13:10:00Z

SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central...

CurePSP Establishes Public Policy and Advocacy Team to Accelerate National Impact

2026-08-13T13:00:00Z

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CurePSP has formally established its Public Policy and Advocacy team with the recent additions of Nora Wong, MPH, Associate Director of Public...

Opción Yo Earns a Place Among the Top 3% of the Inc. 5000

2026-08-13T12:51:07Z

MIAMI, FL, Aug. 13, 2026 (GLOBE NEWSWIRE) -- — This recognition reflects a profound cultural shift as more people prioritize emotional well-being with the same intention they have long invested...

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

2026-08-13T12:51:00Z

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in...

SS Innovations Reports Second Quarter 2026 Financial Results

2026-08-13T12:30:00Z

Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

2026-08-13T12:30:00Z

- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –

PDS Biotech Reports Second Quarter 2026 Financial Results

2026-08-13T12:30:00Z

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today...

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

2026-08-13T12:30:00Z

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge